COVID-19 疫苗工作组与利益冲突。
COVID-19 Vaccine Task Force and Conflicts of Interest.
机构信息
Professor Emeritus, School of Health Policy and Management, York University; Associate Professor, Department of Family and Community Medicine, University of Toronto, Toronto, ON.
出版信息
Healthc Policy. 2022 Feb;17(3):20-27. doi: 10.12927/hcpol.2022.26732.
Abstract
Early in the COVID-19 pandemic, the federal government established a COVID-19 Vaccine Task Force to provide it with recommendations on a wide variety of issues related to vaccines. This article explores how the conflicts of interest of the Task Force members are declared and managed and what the implications are for the advice that they offer to the government. The Canadian government needs to go beyond just managing conflicts and work toward eliminating them on the Task Force.
摘要
在 COVID-19 大流行早期，联邦政府成立了 COVID-19 疫苗工作队，就与疫苗相关的各种问题向其提供建议。本文探讨了工作队成员的利益冲突是如何申报和管理的，以及这对他们向政府提供的建议有何影响。加拿大政府需要做的不仅仅是管理冲突，还要努力消除工作队中的冲突。
相似文献
1
COVID-19 Vaccine Task Force and Conflicts of Interest.
Healthc Policy. 2022 Feb;17(3):20-27. doi: 10.12927/hcpol.2022.26732.
2
Commentary - From Transparency to Accountability: Finding Ways to Make Expert Advice Trustworthy.
Healthc Policy. 2022 Feb;17(3):28-33. doi: 10.12927/hcpol.2022.26731.
3
Canada is no global health leader on COVID-19 vaccine equity.
Lancet. 2021 May 15;397(10287):1803. doi: 10.1016/S0140-6736(21)00888-6.
4
An equitable vaccine delivery system: Lessons from the COVID-19 vaccine rollout in Canada.
PLoS One. 2022 Dec 30;17(12):e0279929. doi: 10.1371/journal.pone.0279929. eCollection 2022.
5
COVID-19 Vaccine Hesitancy in Canada: Content Analysis of Tweets Using the Theoretical Domains Framework.
J Med Internet Res. 2021 Apr 13;23(4):e26874. doi: 10.2196/26874.
6
Inequity in access to vaccines: the failure of the global response to the COVID-19 pandemic.
Salud Colect. 2022 Oct 1;18:e4190. doi: 10.18294/sc.2022.4190.
7
A review of approved COVID-19 vaccines.
Rocz Panstw Zakl Hig. 2021;72(3):245-252. doi: 10.32394/rpzh.2021.0177.
8
International COVID-19 vaccine inequality amid the pandemic: Perpetuating a global crisis?
J Glob Health. 2021 Jul 3;11:03086. doi: 10.7189/jogh.11.03086.
9
Acceptance of a COVID-19 Vaccine Before it is Available in China During the Pandemic.
Int J Public Health. 2021 Oct 25;66:1604092. doi: 10.3389/ijph.2021.1604092. eCollection 2021.
10
The Emergency Use Authorization of Pharmaceuticals: History and Utility During the COVID-19 Pandemic.
Pharmaceut Med. 2021 Jul;35(4):203-213. doi: 10.1007/s40290-021-00397-6. Epub 2021 Aug 28.
引用本文的文献
1
Managing experts' conflicts of interest in the EU Joint Clinical Assessment.
BMJ Open. 2024 Nov 18;14(11):e091777. doi: 10.1136/bmjopen-2024-091777.
2
Addressing conflicts of interest regarding the vaccine in infectious disease outbreaks based on good governance for health approach: a policy brief.
BMC Health Serv Res. 2023 Sep 25;23(1):1028. doi: 10.1186/s12913-023-10020-w.
3
Biopharmaceutical Financialization and Public Funding of Medical Countermeasures (MCMs) in Canada During the COVID-19 Pandemic.
Int J Health Policy Manag. 2023;12:6936. doi: 10.34172/ijhpm.2023.6936. Epub 2023 May 27.
4
Canada and the pharmaceutical industry in the time of COVID-19.
Int J Soc Determinants Health Health Serv. 2023 Oct;53(4):508-517. doi: 10.1177/27551938231195434. Epub 2023 Aug 13.
5
Mobilization of science advice by the Canadian federal government to support the COVID-19 pandemic response.
Humanit Soc Sci Commun. 2023;10(1):19. doi: 10.1057/s41599-023-01501-8. Epub 2023 Jan 17.
6
Commentary - From Transparency to Accountability: Finding Ways to Make Expert Advice Trustworthy.
Healthc Policy. 2022 Feb;17(3):28-33. doi: 10.12927/hcpol.2022.26731.
7
Health Services and Policy Research in Canada: An Editor's Reflections.
Healthc Policy. 2022 Feb;17(3):6-14. doi: 10.12927/hcpol.2022.26735.
本文引用的文献
1
A Ray of Sunshine: Transparency in Physician-Industry Relationships Is Not Enough.
J Gen Intern Med. 2021 Oct;36(10):3194-3198. doi: 10.1007/s11606-021-06657-0. Epub 2021 Mar 10.
2
Declarations of interest by members of Health Canada's special advisory committees and panels: a descriptive study.
CMAJ Open. 2019 May 19;7(2):E334-E340. doi: 10.9778/cmajo.20190010. Print 2019 Apr-Jun.
3
The Sunshine Act: commercial conflicts of interest and the limits of transparency.
Open Med. 2014 Jan 14;8(1):e10-3. eCollection 2014.
4
Medicare, Medicaid, Children's Health Insurance Programs; transparency reports and reporting of physician ownership or investment interests. Final rule.
Fed Regist. 2013 Feb 8;78(27):9457-528.
Zotero 插件